Sie sind hier: Skip Navigation LinksInstitut für Virologie

Dr. med. Melanie Maier

  • ​Fachärztin für Mikrobiologie, Virologie
    und Infektionsepidemiologie
    • Wissenschaftliche Schwerpunkte
      Hepatitis-B-Infektionen, HIV, antivirale Resistenz



Telefon: 0341 - 97 14333

Peer-reviewed ​Publikationen

34. Kiros M, Alemayehu DH, Geberekidan E, Mihret A, Maier M, Abegaz WE, Mulu A (2020) Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1 infected individuals in Ethiopia. Retrovirology. 2020 Sep 29;17(1):33. doi: 10.1186/s12977-020-00542-0, PMID: 3299369

33. Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, Debnath O, Thürmann L, Kurth F, Völker MT, Kazmierski J, Timmermann B, Twardziok S, Schneider S, Machleidt F, Müller-Redetzky H, Maier M, Krannich A, Schmidt S, Balzer F, Liebig J, Loske J, Suttorp N, Eils J, Ishaque N, Liebert UG, von Kalle C, Hocke A, Witzenrath M, Goffinet C, Drosten C, Laudi S, Lehmann I, Conrad C, Sander LE (2020) COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis Eils R.Nat Biotechnol. 2020 Aug;38(8):970-979. doi: 10.1038/s41587-020-0602-4

32. Hayes A, Nguyen D, Andersson M, Antón A, Bailly JL, Beard S, Benschop KSM, Berginc N, Blomqvist S, Cunningham E, Davis D, Dembinski JL, Diedrich S, Dudman SG, Dyrdak R, Eltringham GJA, Gonzales-Goggia S, Gunson R, Howson-Wells HC, Jääskeläinen AJ, López-Labrador FX, Maier M, Majumdar M, Midgley S, Mirand A, Morley U, Nordbø SA, Oikarinen S, Osman H, Papa A, Pellegrinelli L, Piralla A, Rabella N, Richter J, Smith M, Söderlund Strand A, Templeton K, Vipond B, Vuorinen T, Williams C, Wollants E, Zakikhany K, Fischer TK, Harvala H, Simmonds P.J (2020) A European multicentre evaluation of detection and typing methods for human enteroviruses and parechoviruses using RNA transcripts. Med Virol. 2020 Aug;92(8):1065-107

31. Gerhardt F, Maier M, Liebert UG, Platzbecker U, Wang SY, Papp CP, Bock CT, Berg T, van Bömmel F (2020) Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01525-19

30. Hönemann M, Martin D, Pietsch C, Maier M, Bergs S, Bieck E, Liebert UG (2019). Influenza B virus infections in Western Saxony, Germany in three consecutive seasons between 2015 and 2018: analysis of molecular and clinical features. Vaccine

29. Huruy K, Mulu A, Liebert UG, Maier M (2018). HIV-1C proviral DNA for detection of drug resistance mutations. PLoS One, 13, e0205119.

28. Belyhun Y, Liebert UG, Maier M (2018). Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia. PLoS One, 13, e0191970.

27. Harvala H, Broberg E, Benschop K, Berginc N, Ladhani S, Susi P, Christiansen C, McKenna J, Allen D, Makiello P, McAllister G, Carmen M, Zakikhany K, Dyrdak R, Nielsen X, Madsen T, Paul J, Moore C, von Eije K, Piralla A, Carlier M, Vanoverschelde L, Poelman R, Anton A, Lopez-Labrador FX, Pellegrinelli L, Keeren K, Maier M, Cassidy H, Derdas S, Savolainen-Kopra C, Diedrich S, Nordbo S,  Buesa J, Bailly JL, Baldanti F, MacAdam A, Mirand A, Dudman S, Schuffenecker I,   Kadambari S, Neyts J, Griffiths MJ, Richter J, Margaretto C, Govind S, Morley U,  Adams O, Krokstad S, Dean J, Pons-Salort M, Prochazka B, Cabrerizo M,  Majumdar M, Nebbia G, Wiewel M, Cottrell S, Coyle P, Martin J, Moore C,  Midgley S, Horby P, Wolthers K, Simmonds P, Niesters H, Fischer TK (2018). Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. J Clin Virol, 101, 11-17.

26. Belyhun Y, Maier M, Liebert UG (2017). HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia. Antivir Ther, 22(2), 97-111.

25. Mulu A, Maier M, Liebert UG (2017). Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study. PLoS One, 12(10), e0186619.

24. Belyhun Y, Liebert UG, Maier M (2017). Clade homogeneity and low rate of delta virus despite hyperendemicity of hepatitis B virus in Ethiopia. Virol J, 14(1), 176.

23. Belyhun Y, Maier M, Mulu A, Diro E, Liebert UG (2016). Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis, 16(1), 761.

22. Remmerbach TW, Liese J, Krause S, Schiefke I, Schiefke F, Maier M, Liebert UG (2016). No association of oral lichen planus and hepatitis C virus infection in central Germany. Clin Oral Investig, 20(1), 193-197.

21. Gonzalez MD, Langley LC, Buchan BW, Faron ML, Maier M, Templeton K, Walker K, Popowitch EB, Miller MB, Rao A, Liebert UG, Ledeboer NA, Vinje J, Burnham CA (2016). Multicenter Evaluation of the Xpert Norovirus Assay for Detection of Norovirus Genogroups I and II in Fecal Specimens. J Clin Microbiol, 54(1), 142-147.

20. Wald A, Deterding L, Maier M, Liebert UG, Berg T, Wirtz H, Wiegand J (2016). Hepatitis B Vaccination in End-Stage Pulmonary Disease Patients Evaluated for Lung Transplantation: A Retrospective Single-Center Evaluation. Ann Transplant, 21, 368-372.

19. Kant J, Kratzsch J, Maier M, Liebert UG, Berg T, Wiegand J (2016). HBsAg and anti-HCV screening in elderly hospitalized patients of a German tertiary referral centre. Z Gastroenterol, 54(3), 231-237.

18. Huruy K, Maier M, Mulu A, Liebert UG (2015). Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia. J Med Virol, 87(6), 978-984.

17. Mulu A, Maier M, Liebert UG (2015). Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. PLoS One, 10(10), e0141318.

16. Mulu A, Maier M, Liebert UG (2015). Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates. J Transl Med, 13(1), 377-384.

15. Mulu A, Maier M, Liebert UG (2014). Triple NF-kB binding sites and LTR sequence similarities in HIV-1C isolates irrespective of helminth co-infection. Parasit Vectors, 7(1), 204.

14. Mulu A, Lange T, Liebert UG, Maier M (2014). Clade homogeneity and Pol gene polymorphisms in chronically HIV-1 infected antiretroviral treatment naive patients after the roll out of ART in Ethiopia. BMC Infect Dis, 14, 158.

13. Mulu A, Liebert UG, Maier M (2014). Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infect Dis, 14, 28.

12. Poelman R, Schuffenecker I, Van Leer-Buter C, Josset L, Niesters HG, Lina B; ESCV-ECDC EV-D68 study group (2015). European surveillance for enterovirus D68 during the emerging North-American outbreak in 2014. J Clin Virol, 71, 1-9.

11. Mulu A, Maier M, Liebert UG (2013). Deworming of intestinal helminths reduces HIV-1 subtype C viremia in chronically co-infected individuals. Int J Infect Dis, 17(10), 897-901.

10. Maier M, Liebert UG, Wittekind C, Kaiser T, Berg T, Wiegand J (2013). Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. PLoS One, 8(6), e67481.

9. Kant J, Moller B, Heyne R, Herber A, Bohm S, Maier M, Liebert UG, Mossner J, Berg T, Wiegand J (2013). Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection. Eur J Gastroenterol Hepatol, 25(4), 416-420.

8. Abreha T, Woldeamanuel Y, Pietsch C, Maier M, Asrat D, Abebe A, Hailegiorgis B, Aseffa A, Liebert UG (2011). Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia. J Med Virol, 83(5), 776-782.

7. Karlas T, Hartmann J, Weimann A, Maier M, Bartels M, Jonas S, Mossner J, Berg T, Tillmann HL, Wiegand J (2011). Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis, 13(3), 299-302.

6. Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I (2011). Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort. Z Gastroenterol, 49(11), 1463-1469.

5. Basara N, Rasche FM, Schwalenberg T, Wickenhauser C, Maier M, Ivovic J, Niederwieser D, Lindner TH (2010). Hydronephrosis Resulting from Bilateral Ureteral Stenosis: A Late Complication of Polyoma BK Virus Cystitis? J Transplant, 2010, e297358.

4. Grunewald S, Bodendorf M, Maier M, Simon JC, Paasch U (2009). Parietal scalp necrosis: an unusual manifestation of giant cell arteritis. Dermatology, 219(3), 282-284.

3. Ganepola S, Gentilini C, Hilbers U, Lange T, Rieger K, Hofmann J, Maier M, Liebert UG, Niederwieser D, Engelmann E, Heilbronn R, Thiel E, Uharek L (2007). Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant, 39(5), 293-299.

2. Schiefke I, Klecker C, Maier M, Oesen U, Etzrodt G, Tannapfel A, Liebert UG, Berr F (2004). Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. Liver Int, 24(2), 98-104.

1. Maier M, Tröbs R, Schütz A, Pernice W, Körholz D (2003). Infantile malignant peripheral nerve sheath tumour of the ileum causing ileo-ileal intussusception in an infant. Eur J Pediatr Surg, 13, 347-9.

Sonstige Publikationen

3. Schlegel M, Stekeler-Weithofer P, Schildberger K, Voss T, Liebert UG, Maier M, Seiwert H, Kreher K, Beck-Sickinger A, Petzoldt M (2009). Virale Evolution - Koevolution von Virus und Wirt. In: Beck-Sickinger A, Petzoldt M, Paradigma Evolution - Chancen und Grenzen eines Erklärungsmusters. (S. 87-104), Frankfurt am Main: Peter Lang GmbH Internationaler Verlag der Wissens.

2. Maier M, Liebert UG (2009). Paramyxoviren. In: Neumeister B, Geiss H, Braun R, Kimmig P, Mikrobiologische Diagnostik: Bakteriologie - Mykologie - Virologie - Parasitologie. (S. 913-927), Stuttgart: Thieme Verlag KG.

1. Engelhardt J, Hügle B, Bigl A, Maier M, Liebert UG, Strehlau J, Schuster V (2008). Chronische Hepatitis C im Kindesund Jugendlichenalter - Ist die Kombination von pegyliertem Interferon alfa-2 plus Ribavirin zukünftig die Therapie der Wahl? Kinder- und Jugendmedizin, 8, 512-514.

Johannisallee 30, Haus J
04103 Leipzig
0341 - 97 14300
0341 - 97 14309